Venture Capitalists Freeze Funding For Some U.S. Start-ups, But Could Channel More Investment Into China Health Care
This article was originally published in PharmAsia News
Executive Summary
BEIJING - While the Western world's financial maelstrom is already choking off funding for some biotech start-ups in the U.S., it could have the opposite effect in China, and trigger the flow of more capital into promising Chinese healthcare outfits, according to a partner in a half-billion-dollar venture capital firm
You may also be interested in...
Sinobiomed’s New U.S. Leadership Seeks Licensing Deals, Strategic Investment From Global Pharma
Chinese firm’s board brings in a slate of U.S. execs to engineer a turnaround after Sinobiomed's valuation drops from $400 million to $10 million.
To Engineer Recovery, Sinobiomed’s New American Leaders Seek Licensing Deals, Strategic Investment From Global Pharma
BEIJING - Aiming to reverse a 97.5 percent decline in the company's valuation over the past two years, the board of directors of Sinobiomed has appointed a team of American executives charged with engineering a recovery
Sinobiomed’s New U.S. Leadership Seeks Licensing Deals, Strategic Investment From Global Pharma
Chinese firm’s board brings in a slate of U.S. execs to engineer a turnaround after Sinobiomed's valuation drops from $400 million to $10 million.